

Effects of Maraviroc versus Tenofovir DF on Bone Loss
A5303 Trial

Bone Effects of Maraviroc vs. Tenofovir DF, with DRV + RTV + FTC

A5303: Study Design

Study Design: A5303 Study

- **Background:** Phase 2b, prospective, double-blind, placebo-controlled study evaluating the effects of maraviroc versus tenofovir DF on bone loss in HIV-infected, treatment-naïve patients
- **Inclusion Criteria (n = 262)**
 - Age ≥ 18
 - Antiretroviral-naïve patients
 - R-5 tropic virus
 - HIV RNA >1000 copies/mL
- **Treatment Arms***
 - MVC + DRV + RTV + FTC
 - TDF + DRV + RTV + FTC

MVC + DRV + RTV + FTC
(n = 130)


TDF + DRV + RTV + FTC
(n = 129)

*Dosing: Maraviroc 150 mg QD + Darunavir 800 mg QD + Ritonavir 100 mg QD + Emtricitabine 200 mg QD

*Dosing: Tenofovir 300 mg QD + Emtricitabine 200 mg QD + Darunavir 800 mg QD + Ritonavir 100 mg QD

Bone Effects of Maraviroc vs. Tenofovir DF, with DRV + RTV + FTC A5303: Results


Week 48: Changes in Bone Mineral Density from Baseline



Source: Taiwo B, et al. Clin Infect Dis. 2015;61:1179-88.

Bone Effects of Maraviroc vs. Tenofovir DF, with DRV + RTV + FTC A5303: Results

Week 48: Virologic Response



Statistical Analysis

Source: Taiwo B, et al. Clin Infect Dis. 2015;61:1179-88.

Bone Effects of Maraviroc vs. Tenofovir DF, with DRV + RTV + FTC A5303: Conclusions

Conclusions: “Maraviroc was associated with less bone loss at the hip and lumbar spine compared with tenofovir DF. Maraviroc may be an option to attenuate ART-associated bone loss.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

